End-point definition and trial design to advance tuberculosis vaccine development.

Saved in:
Bibliographic Details
Title: End-point definition and trial design to advance tuberculosis vaccine development.
Authors: Garcia-Basteiro AL; Centro de Investigação em Sade de Manhiça (CISM), Maputo, Mozambique alberto.garcia-basteiro@manhica.net.; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECT), Barcelona, Spain., White RG; London School of Hygiene and Tropical Medicine, London, UK., Tait D; International AIDS Vaccine Initiative (IAVI) NPC, Cape Town, South Africa., Schmidt AC; Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA., Rangaka MX; Institute for Global Health and MRC Clinical Trials Unit at University College London, London, UK.; CIDRI-AFRICA, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Quaife M; London School of Hygiene and Tropical Medicine, London, UK., Nemes E; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Dept of Pathology, University of Cape Town, Cape Town, South Africa., Mogg R; Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Hill PC; Centre for International Health, University of Otago, Dunedin, New Zealand., Harris RC; London School of Hygiene and Tropical Medicine, London, UK.; Sanofi Pasteur, Singapore., Hanekom WA; Africa Health Research Institute, KwaZulu-Natal, South Africa.; Division of Infection and Immunity, University College London, London, UK., Frick M; Treatment Action Group, New York, NY, USA., Fiore-Gartland A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Evans T; Vaccitech, Oxford, UK., Dagnew AF; Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA., Churchyard G; The Aurum Institute, Parktown, South Africa.; Vanderbilt University, Nashville, TN, USA.; University of the Witwatersrand, Johannesburg, South Africa., Cobelens F; Dept of Global Health and Amsterdam Institute for Global health and development, Amsterdam University Medical Centres, Amsterdam, The Netherlands., Behr MA; Dept of Medicine, McGill University; McGill International TB Centre, Montreal, QC, Canada., Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Dept of Pathology, University of Cape Town, Cape Town, South Africa.
Source: European respiratory review : an official journal of the European Respiratory Society [Eur Respir Rev] 2022 Jun 07; Vol. 31 (164). Date of Electronic Publication: 2022 Jun 07 (Print Publication: 2022).
Publication Type: Journal Article; Review
Journal Info: Publisher: European Respiratory Society Country of Publication: England NLM ID: 9111391 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1600-0617 (Electronic) Linking ISSN: 09059180 NLM ISO Abbreviation: Eur Respir Rev Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1600-0617
DOI:10.1183/16000617.0044-2022